Barbexaclone

Barbexaclone, a salt compound of propylhexedrine and phenobarbital, is a potent antiepileptic. By weight, barbexaclone is 40% propylhexedrine and 60% phenobarbital. While barbexaclone has sedative properties, propylhexedrine has psychostimulant properties intended to offset these sedative effects. Pharmacokinetic studies have demonstrated that the pharmacokinetics of phenobarbital given as barbexaclone are not affected by propylhexedrine. Several reports from Spanish and Italian literature suggest that barbexaclone is at least as effective as phenobarbital in adults and children, while being better tolerated and having less sedative properties. It is grouped under the following drug class(es): Barbiturates. Its therapeutic use is listed as anticonvulsants. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Maliasin, Barbexaclonum and Barbexaclona. It is listed as a controlled drug substance (Schedule IV). Its PubChem CID is 71196.